Download PDF
Horm Metab Res 2021; 53(10): 683-691
DOI: 10.1055/a-1639-1024
Endocrine Care

Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer

Seher Çetinkaya Altuntaş 
1   Endocrinology Department, Recep Tayyip Erdoğan University, Rize, Turkey
,
Çiçek Hocaoğlu
2   Psychiatrics Department, Recep Tayyip Erdoğan University, Rize, Turkey
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

In differentiated thyroid cancer (DTC), the standard treatment includes total thyroidectomy and lifetime levothyroxine (LT4) replacement. However, long-term exogenous LT4 has become controversial due to the adverse effects of oversuppression. The study included 191 patients (aged 18–76 years) with a prospective diagnosis of non-metastatic DTC and 79 healthy individuals. The patients with DTC were stratified into three groups according to their TSH levels: suppressed thyrotropin if TSH was below 0.1 μIU/ml, mildly suppressed thyrotropin if TSH was between 0.11 and 0.49 μIU/ml, and low-normal thyrotropin if THS was between 0.5 and 2 μIU/ml. The Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Anxiety Sensitivity Index (ASI), Short Symptom Inventory (SSI), and Pittsburgh Sleep Quality Index (PSQI) were administered to all participants. It was found that the BDI, BAI, SSI and PSQI scores were worse in patients with DTC (p=0.024, p=0.014, p=0.012, and p=0.001, respectively). According to theTSH levels, the mean ASI was found to be higher in the suppressed and mildly suppressed thyrotropin groups (19±14.4 vs. 10.6±11.1; 16.4±14.9 vs. 10.6±11.1, p=0.024, respectively), the mean SSI was found higher in the suppressed group (61.0±55.5 vs. 35.1±37.0, p=0.046), and the mean PSQI was higher in all three groups (7.94±3.97 vs. 5.35±4.13; 7.21±4.59 vs. 5.35±4.13; 7.13±4.62 vs. 5.35±4.13, p=0.006) when compared with the controls. No significant difference was found between the groups. A positive correlation was detected in the duration of LT4 use and BDI and SSI, and a weak, negative correlation was detected between TSH levels and ASI and PSQI. Based on our study, it was found that depression, anxiety disorders, and sleep problems were more prevalent in patients with DTC, being more prominent in the suppressed TSH group. These results were inversely correlated with TSH values and positively correlated with the duration of LT4 use. Unnecessary LT4 oversuppression should be avoided in patients with DTC.

Key words

differentiated thyroid cancer - levothyroxine - subclinical hyperthyroidism - thyroid-stimulating hormone


Publication History

Received: 02 July 2021

Accepted after revision: 30 August 2021

Article published online:
04 October 2021

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Tagay S, Herpertz S, Langkafel M. et al Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol 2005; 153: 755-763
    CrossrefPubMedGoogle Scholar
  • 2 Türkiye Endokrinoloji ve Metabolizma Derneği, Tiroid Hastalıkları Tanı ve Tedavi Kılavuzu 2019; 179-181
    PubMed
  • 3 Haugen BR, Alexander EK, Bible KC. et al 2015 American thyroid association management guidelines for adult Patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1-133
    CrossrefPubMedGoogle Scholar
  • 4 Botella-Carretero JI, Galan JM. Caballero. et al Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2003; 10: 601-610
    CrossrefPubMedGoogle Scholar
  • 5 Eustatia-Rutten CF, Corssmit EP, Pereira AM. et al Quality of life in long-term exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol 2006; 64: 284-291
    CrossrefPubMedGoogle Scholar
  • 6 Sartorius N, Ustün TB, Lecrubier Y. et al Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl 1996; 30: 38-43
    CrossrefPubMedGoogle Scholar
  • 7 Taylor S. Anxiety sensitivity: Theoretical perspectives and recent findings. Behaviour Research and Therapy 1995; 33: 243-258
    CrossrefPubMedGoogle Scholar
  • 8 Placidi GP, Boldrini M, Patronelli A. et al Prevalence of psychiatric disorders in thyroid diseased patients. Neuropsychobiology 1998; 38: 222-225
    CrossrefPubMedGoogle Scholar
  • 9 Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001; 2: 297-307
    CrossrefPubMedGoogle Scholar
  • 10 Berger AM. Update on the state of the science: sleep-wake disturbances in adult patients with cancer. Oncol Nurs Forum 2009; 36: E165-E177
    CrossrefPubMedGoogle Scholar
  • 11 Akatsu H, Ewing SK, Stefanick ML. et al The association between thyroid function and objective and subjective sleep quality in older men: the osteoporotic fractures in men (MrOS) study. Endocr Pract 2014; 20: 576-586
    CrossrefPubMedGoogle Scholar
  • 12 He Y, Meng Z, Jia Q. et al Sleep quality of patients with differentiated thyroid cancer. PLoS One 2015; 10: e0130634
    CrossrefPubMedGoogle Scholar
  • 13 Underbjerg L, Sikjaer T, Mosekilde L. et al Postsurgical hypoparathyroidism risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res 2014; 29: 2504-2510
    CrossrefPubMedGoogle Scholar
  • 14 Taylor S, Cox BJ. Anxiety sensitivity: Multiple dimensions and hierarchic structure. Behav Res Ther 1998; 36: 37-51
    CrossrefPubMedGoogle Scholar
  • 15 Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7: 613-619
    CrossrefPubMedGoogle Scholar
  • 16 Ittermann T, VoÈlzke H, Baumeister SE. et al Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol 2015; 50: 1417-1425
    CrossrefPubMedGoogle Scholar
  • 17 Bauer M, Heinz A, Whybrow PC. Thyroid hormones, serotonin and mood of synergy and significance in the adult brain. Mol Psychiatr 2002; 7: 140-156
    CrossrefPubMedGoogle Scholar
  • 18 Prange A, Lara PP, Wilson IC. et al Effects of thyrotropin-releasing hormone in depression. Lancet 1972; 2: 999-1002
    CrossrefPubMedGoogle Scholar
  • 19 Dietrich JW, Landgrafe-Mende G, Wiora E. et al Calculated parameters of thyroid homeostasis: Emerging tools for differential diagnosis and clinical research. Front Endocrinol 2016; 7: 57
    CrossrefPubMedGoogle Scholar
  • 20 Biondi B, Palmieri EA, Fazio S. et al Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000; 85: 4701-4705
    PubMedGoogle Scholar
  • 21 Sgarbi JA, Villaca FG, Garbeline B. et al The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003; 88: 1672-1677
    CrossrefPubMedGoogle Scholar
  • 22 Larisch R, Kley K, Nikolaus S. et al Depression and anxiety in different thyroid function states. Horm Metab Res 2004; 36: 650-653
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Sait GM, Kisakol G, Savas CA. et al Assessment of anxiety in subclinical thyroid disorders. Endocr J 2004; 51: 311-315
    CrossrefPubMedGoogle Scholar
  • 24 Stott DJ, McLellan AR, Finlayson J. et al Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at increased risk of developing overt hyperthyroidism. Quart J Med 1991; 78: 77-84
    PubMedGoogle Scholar
  • 25 Bommer M, Eversmann T, Pickardt R. et al Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism. Klin Wochenschr 1990; 68: 552-558
    CrossrefPubMedGoogle Scholar
  • 26 Biondi B, Fazio S, Carella C. et al Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long-term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1994; 78: 1028-1033
    PubMedGoogle Scholar
  • 27 Shapiro LE, Sievert R, Ong L. et al Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of 1-thyroxine. J Clin Endocrinol Metab 1997; 82: 2592-2595
    PubMedGoogle Scholar
  • 28 Samuels MH, Kolobova I, Smeraglio A. et al The effects of levothyroxine replacement or suppressive therapy on health status, mood, and cognition. J Clin Endocrinol Metab 2014; 99: 843-851
    CrossrefPubMedGoogle Scholar
  • 29 Hoftijzer HC, Heemstra KA, Corssmit EP. et al Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008; 93: 200-203
    CrossrefPubMedGoogle Scholar
  • 30 Diessl S, Holzberger B, Mader U. et al Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin Endocrinol 2012; 76: 586-592
    CrossrefPubMedGoogle Scholar
  • 31 Crevenna R, Zettinig G, Keilani M. et al Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy. Suppor Care Cancer 2003; 11: 597-603
    CrossrefPubMedGoogle Scholar
  • 32 Medici M, Direk N, Visser WE. et al Thyroid function within the normal range and the risk of depression: a population-based cohort study. J Clin Endocrinol Metab 2014; 99: 1213-1219
    CrossrefPubMedGoogle Scholar
  • 33 Panicker V, Evans J, Bjoro T. et al A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin Endocrinol (Oxf) 2009; 71: 574-580
    CrossrefPubMedGoogle Scholar
  • 34 Lee S, Oh SS, Park EC. et al Sex differences in the association between thyroid-stimulating hormone levels and depressive symptoms among the general population with normal free T4 levels. J Affect Disord 2019; 249: 151-158
    CrossrefPubMedGoogle Scholar
  • 35 Walsh JohnP, Lynley C. et al Stuckey small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab 2006; 91: 2624-2630
    CrossrefPubMedGoogle Scholar
  • 36 Williams MD, Harris R, Dayan CM. et al Thyroid function and the natural history of depression: findings from the caerphilly prospective study (CaPS) and a meta-analysis. Clin Endocrinol (Oxf) 2009; 70: 484-492
    CrossrefPubMedGoogle Scholar
  • 37 Pelttari H, Sintonen H, Schalin-Jäntti C. et al Health-related quality of life in long-term follow-up of patients with cured TNM Stage I or II differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2009; 70: 493-497
    CrossrefPubMedGoogle Scholar
  • 38 Kim W, Lee J, Ha J. et al Association between sleep duration and subclinical thyroid dysfunction based on nationally representative data. J Clin Med 2019; 18: 2010
    CrossrefPubMedGoogle Scholar